This study, published in Frontiers in Cellular and Infection Microbiology, explores how Lentinan (LNT)—a polysaccharide extracted from shiitake mushrooms—can act as a potent defense against Influenza A. By modulating the immune system's signaling pathways, LNT prevents the lethal "cytokine storms" that often lead to severe lung injury during viral infections.
TL;DR
Researchers demonstrated that Lentinan (LNT) significantly improves survival rates and reduces lung damage in mice infected with H1N1 influenza. The compound works by downregulating the TLR4/MyD88 signaling pathway, effectively "turning down the volume" on the body's overactive inflammatory response.
What Problem Does This Paper Address?
Influenza A virus (IAV) remains a persistent global health threat, not just because of the virus itself, but because of how our bodies react to it. In severe cases, the immune system overreacts, releasing a flood of pro-inflammatory proteins called cytokines. This "cytokine storm" leads to Acute Lung Injury (ALI), which is a primary cause of mortality.
While antiviral drugs like Oseltamivir (Tamiflu) exist, the rise of drug-resistant strains creates an urgent need for new therapies. Specifically, researchers are looking for immunomodulators: drugs that don't just attack the virus, but help the host manage the immune response more effectively. Lentinan (LNT) has shown promise in cancer and general inflammation, but its specific in vivo (in a living organism) mechanisms against influenza were previously unclear.
Methods
The researchers used an ICR mouse model, dividing 120 mice into six groups:
- Control: Healthy mice.
- Model: Infected with H1N1 but untreated.
- Oseltamivir: Positive control group receiving standard antiviral treatment.
- LNT-L, LNT-M, LNT-H: Infected mice receiving low, medium, and high doses of Lentinan (5, 10, and 20 mg/kg).
Mice were infected intranasally with the A/PR/8/34 (H1N1) strain. The team monitored survival, weight, and clinical signs for 14 days. At the 5-day mark (peak infection), they analyzed lung tissue, viral titers, and blood indices. Crucially, they used RT-qPCR and Immunohistochemistry (IHC) to track the expression of proteins in the TLR4/MyD88 signaling pathway, which acts as a "master switch" for inflammation.
Datasets
This study relied on primary experimental data generated from:
- ICR Mouse Cohorts: 120 male mice (18-20g).
- Viral Strain: Influenza A virus A/PR/8/34 (H1N1).
- Molecular Data: Primer sequences for RT-qPCR targeting TNF-$\alpha$, IL-1$\beta$, IL-4, IL-5, IL-6, IFN-$\gamma$, TLR4, MyD88, TRAF6, and NF-$\kappa$B p65.
Key Insights and Ideas
- Dose-Dependent Protection: The higher the dose of LNT, the better the outcome. The high-dose group (LNT-H) showed the least weight loss and the fastest recovery.
- The "Goldilocks" Immune Response: LNT didn't just suppress the immune system; it balanced it. It lowered pro-inflammatory cytokines (like IL-6 and TNF-$\alpha$) that cause tissue damage, while simultaneously increasing IFN-$\gamma$, a cytokine essential for clearing the virus.
- Pathway Inhibition: The study pinpointed the TLR4/MyD88/NF-$\kappa$B axis as the specific target. By inhibiting this pathway, LNT prevents the signal that tells the body to keep producing inflammatory cytokines, effectively halting the cytokine storm before it destroys lung tissue.
- Lung Preservation: Histopathology showed that LNT-treated mice had significantly less alveolar thickening and inflammatory cell infiltration compared to the untreated "model" group.
Key Results
- Survival Rate: The high-dose LNT group achieved a 60% survival rate, compared to 0% in the untreated model group.
- Viral Titer: LNT significantly reduced the amount of virus present in the lungs, though Oseltamivir remained slightly more effective at direct viral reduction.
- Lung Index: LNT treatment significantly lowered the "lung coefficient" (a measure of inflammation and edema), indicating healthier, less congested lungs.
- Blood Markers: LNT helped maintain higher levels of white blood cells, lymphocytes, and monocytes, which are typically depleted during severe IAV infection.
Limitations and Future Work
While the results are promising, the authors and the study design note a few areas for further exploration:
- Scope of Strains: The study focused on one specific H1N1 strain. Future research needs to confirm if LNT is equally effective against other subtypes like H3N2 or highly pathogenic avian influenza (H5N1).
- Timing: Treatment was administered 2 hours post-infection. In a real-world clinical setting, patients often seek treatment days after symptoms appear; testing LNT's efficacy as a "late-stage" intervention is necessary.
- Human Translation: While ICR mice are a standard model, human immune systems are more complex. Clinical trials will be required to determine if these mushroom-derived polysaccharides can be a viable adjunct therapy for human flu patients or even those suffering from other respiratory viruses like COVID-19.
Summary updated